Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy as neoadjuvant therapy for locally advanced cervical cancer
ChiCTR2600122075Phase 4Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in Cervical Cancer (CC), sponsored by Hunan Cancer Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600122075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122075.